Navigation Links
Data Available from Erbitux Phase III Study in First-Line Treatment,of Advanced Pancreatic Cancer

NEW YORK, April 10, 2007 /PRNewswire-FirstCall/ -- ImClone Systems Incorporated and Bristol-Myers Squibb Company today announced that a Phase III study of ERBITUX(R) (Cetuximab) plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival.

Conducted by the Southwest Oncology Group (SWOG), a cancer center network sponsored by the National Cancer Institute, the open-label, randomized study compared ERBITUX plus gemcitabine to gemcitabine alone in more than 700 patients with pancreatic cancer in the first-line treatment setting. The study was conducted in centers throughout the United States and Canada. It was completed in a significantly shorter time than projected, providing a timely answer to an important research question. SWOG has informed ImClone and Bristol-Myers Squibb that the primary study endpoint of statistically improving overall survival was not met. The three parties -- SWOG, ImClone, and Bristol-Myers Squibb -- will engage in joint efforts to fully interpret these results.

"This study was designed to examine the Phase II results we previously observed for ERBITUX in patients with pancreatic cancer," stated Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems. "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."

"Pancreatic cancer is a devastating disease with few effective treatment options, and it is unfortunate that the use of ERBITUX in this trial has not demonstrated the benefit it has shown in other tumors," said Martin Birkhofer, M.D., Vice President, Oncology Global Medical Affa
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Positive Results Prompt US National Cancer Institute to Make Glivec Available to Patients in Post-Surgical GIST Study
3. Positive Results Prompt US National Cancer Institute to Make Gleevec Available To Patients in Post-Surgical Gist Study
4. Survival Data Available From Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
5. Survival Data Available from Erbitux Study in First-Line Treatment of Advanced Head and Neck Cancer
6. Extensive Clinical Data on Erbitux Presented at the 2007 ASCO Annual Meeting
7. Merck at ASCO 2007: Spectrum of Studies Reinforces Promise of Erbitux for Colorectal and Head and Neck Cancer Patients
8. Randomized Phase III Trial Showed Erbitux Significantly Improved Secondary Endpoints of Progression-Free Survival and Disease Control in Metastatic Colorectal Cancer Patients
9. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
11. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
(Date:8/21/2014)... Texas , Aug. 21, 2014  eRelevance ... services company, announced today that it has completed ... (EMR) solution for Plastic Surgery and Dermatology practices. ... even more value to healthcare practices using Nextech," ... of eRelevance Corporation. "Using information from the EMR ...
(Date:8/21/2014)... , Aug. 21, 2014 The spinal column is ... human body. Signals carried to and from the brain through ... and nervous system. Injury or ailment here can be life ... a loss of control over their body. Though back injury ... person,s life, there are more options available to make things ...
(Date:8/21/2014)... Aug. 21, 2014  Publicis Groupe customer engagement ... Managing Partner and Healthcare Industry Group Leader, has been ... recognizes the most inspiring people in the life-sciences industry. ... research and development, marketing, technology, creativity, strategy and medicine. ... as a partner in its leading Rosetta Consulting practice. ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Shannon Hartley Shines in PharmaVOICE 100 2
... Cell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: ... of the peer reviewed journal, Leukemia & ... of a phase I/II clinical trial evaluating the ... in treating patients with aggressive non-Hodgkin,s lymphoma ("NHL") ...
... BASKING RIDGE, N.J., April 3, 2011 Regado Biosciences, ... antithrombotic aptamers with active control agents, announced today the ... of the company,s lead product, the anticoagulation system REG1, ... Cardiology 2011 60th Annual Scientific Session & Expo in ...
Cached Medicine Technology:Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 2Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 3Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 4Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 5Substitution of Pixantrone for Doxorubicin in CHOP Chemotherapy Regimen Produces High Rates of Complete Remissions and Long-Term Disease Free Survival in Patients with Relapsed/Refractory Aggressive NHL Who Previously Failed Frontline CHOP Therapy 6Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 2Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 3Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 4Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System 5
(Date:8/21/2014)... FL (PRWEB) August 21, 2014 The ... published today in The Journal of the American Medical ... more invasive cancers and reduces unnecessary recalls. Memorial Healthcare ... in the study. , “This study confirms what we ... invasive, harmful cancers we want to find and, at ...
(Date:8/21/2014)... 21, 2014 Xarelto lawsuit ( http://www.xareltolawsuitcenter.com/ ... to suffer uncontrollable internal bleeding and other serious injuries ... reports. According to court documents, a wrongful death lawsuit ... Easter District of New York by the family of ... event that was allegedly caused by Xarelto. Among other ...
(Date:8/21/2014)... UK (PRWEB) August 21, 2014 The ... USD 15.6 billion in 2014 and reach USD 18.3 ... the forecast period. The drivers of such growth include ... rising obese and diabetic population, and surging ageing population. ... of state-of-the-art wound care products. Region-wise, North America leads ...
(Date:8/21/2014)... 2014 The report "Industrial Flue ... Control System (FGD, DeNOx, Particulate Control, Mercury Control) ... Chemical & Others) - Global Trends & Forecasts ... flue gas treatment systems & services market with ... in terms of value. The industrial flue gas ...
(Date:8/21/2014)... NY (PRWEB) August 21, 2014 ... products manufactured by Boston Scientific has begun in ... first bellwether trial. The Rottenstein Law Group LLP, ... women with claims of harm stemming from the ... a claim for compensation for injuries suffered at ...
Breaking Medicine News(10 mins):Health News:Dr. Mary Hayes: Study Shows 3D Mammography Finds More Invasive Cancers While Reducing Unnecessary Recalls 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 3Health News:Xarelto Lawsuits Mount With New Filing in New York Federal Court, Bernstein Liebhard LLP Reports 4Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 2Health News:Global Wound Care Market to Post 3.2% CAGR Through 2019, Says MarketsandMarkets in Its New Report Published at MarketPublishers.com 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 2Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 3Health News:Industrial Flue Gas Treatment Systems Market Estimated to Worth $59, 546.7 Million by 2019 – Report by MarketsandMarkets 4Health News:Transvaginal Mesh Lawsuit News: Second Boston Scientific Mesh Bellwether Trial Begins, The Rottenstein Law Group LLP Reports 2
... found that there is an increase in number of children ... to tackle young criminals. According to the statistics the number ... offences due to alcohol increased by more than 150 % ... and theft. But the figures of the number of juveniles ...
... of us, reading others body language comes easy and ... people with schizophrenia,// may have a difficulty and ... ,But people with schizophrenia, even those who have ... fluent in understanding body language, according to a University ...
... are participating in the anti-reservation protest have stated that ... Government rolls back plans for reservation of seats in ... 300 have been provided with termination notices. ... government hospitals entered the eighth day Friday, students from ...
... Meeting of the American Society of Hypertension in New ... sexual dysfunction// (FSD) and high blood pressure. According to ... increased hypertension and increased age suffer from FSD. Female ... in sexual desire, persistent or recurring decrease in sexual ...
... being subjected to unnecessary stress as doctor’s order unwanted ... medical tests put a huge strain on the U.S. ... year. The study, conducted by researchers at the Georgetown ... published in the June issue of the American Journal ...
... from Copenhagen, the Danish authorities on Thursday have reported the ... // ,The Danish Veterinary and Food Administration ... a private farm near the city of Kerteminde in the ... hundred chickens, ducks and geese on the farm have been ...
Cached Medicine News:Health News:Schizophrenia impairs body language comprehension 2Health News:Schizophrenia impairs body language comprehension 3Health News:Doctors Urge Government To Roll Back Quotas 2Health News:Link Established Between FSD and High Blood Pressure 2Health News:U.S. Doctors Order Unwanted Medical Tests 2Health News:U.S. Doctors Order Unwanted Medical Tests 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: